1. Home
  2. OLMA vs VLY Comparison

OLMA vs VLY Comparison

Compare OLMA & VLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • VLY
  • Stock Information
  • Founded
  • OLMA 2006
  • VLY 1927
  • Country
  • OLMA United States
  • VLY United States
  • Employees
  • OLMA N/A
  • VLY N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • VLY Major Banks
  • Sector
  • OLMA Health Care
  • VLY Finance
  • Exchange
  • OLMA Nasdaq
  • VLY Nasdaq
  • Market Cap
  • OLMA 299.7M
  • VLY N/A
  • IPO Year
  • OLMA 2020
  • VLY N/A
  • Fundamental
  • Price
  • OLMA $4.57
  • VLY $9.64
  • Analyst Decision
  • OLMA Strong Buy
  • VLY Buy
  • Analyst Count
  • OLMA 4
  • VLY 13
  • Target Price
  • OLMA $24.50
  • VLY $10.54
  • AVG Volume (30 Days)
  • OLMA 962.9K
  • VLY 10.8M
  • Earning Date
  • OLMA 08-05-2025
  • VLY 07-24-2025
  • Dividend Yield
  • OLMA N/A
  • VLY 4.55%
  • EPS Growth
  • OLMA N/A
  • VLY N/A
  • EPS
  • OLMA N/A
  • VLY 0.69
  • Revenue
  • OLMA N/A
  • VLY $1,520,316,000.00
  • Revenue This Year
  • OLMA N/A
  • VLY $34.12
  • Revenue Next Year
  • OLMA N/A
  • VLY $8.89
  • P/E Ratio
  • OLMA N/A
  • VLY $13.98
  • Revenue Growth
  • OLMA N/A
  • VLY N/A
  • 52 Week Low
  • OLMA $2.86
  • VLY $6.56
  • 52 Week High
  • OLMA $16.62
  • VLY $11.10
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 52.70
  • VLY 69.30
  • Support Level
  • OLMA $4.12
  • VLY $8.82
  • Resistance Level
  • OLMA $4.70
  • VLY $9.05
  • Average True Range (ATR)
  • OLMA 0.31
  • VLY 0.22
  • MACD
  • OLMA 0.04
  • VLY 0.09
  • Stochastic Oscillator
  • OLMA 74.73
  • VLY 97.01

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Share on Social Networks: